Developing dietary interventions as therapy for cancer
SR Taylor, JN Falcone, LC Cantley… - Nature Reviews …, 2022 - nature.com
Cancer cells acquire distinct metabolic preferences based on their tissue of origin, genetic
alterations and degree of interaction with systemic hormones and metabolites. These …
alterations and degree of interaction with systemic hormones and metabolites. These …
[HTML][HTML] mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy
T Tian, X Li, J Zhang - International journal of molecular sciences, 2019 - mdpi.com
The mammalian or mechanistic target of rapamycin (mTOR) pathway plays a crucial role in
regulation of cell survival, metabolism, growth and protein synthesis in response to upstream …
regulation of cell survival, metabolism, growth and protein synthesis in response to upstream …
[HTML][HTML] Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
M Chevallier, M Borgeaud, A Addeo… - World Journal of …, 2021 - ncbi.nlm.nih.gov
Lung cancer, of which non-small lung cancer is the most common subtype, represents the
leading cause of cancer related-death worldwide. It is now recognized that a significant …
leading cause of cancer related-death worldwide. It is now recognized that a significant …
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor …
S Lu, L Wu, H Jian, Y Cheng, Q Wang… - The Lancet …, 2023 - thelancet.com
Background In the first interim analysis of the ORIENT-31 trial, compared with chemotherapy
alone, sintilimab plus bevacizumab biosimilar IBI305 plus chemotherapy (pemetrexed and …
alone, sintilimab plus bevacizumab biosimilar IBI305 plus chemotherapy (pemetrexed and …
Inhibition of the PI3K/AKT/mTOR pathway in solid tumors
PM LoRusso - Journal of clinical oncology, 2016 - ascopubs.org
The phosphoinositide 3-kinase (PI3K) pathway plays an integral role in many cellular
processes and is frequently altered in cancer, contributing to tumor growth and survival …
processes and is frequently altered in cancer, contributing to tumor growth and survival …
Hallmarks of the ageing lung
S Meiners, O Eickelberg… - European Respiratory …, 2015 - Eur Respiratory Soc
Ageing is the main risk factor for major non-communicable chronic lung diseases, including
chronic obstructive pulmonary disease, most forms of lung cancer and idiopathic pulmonary …
chronic obstructive pulmonary disease, most forms of lung cancer and idiopathic pulmonary …
TP 53 mutations in human cancer: database reassessment and prospects for the next decade
B Leroy, M Anderson, T Soussi - Human mutation, 2014 - Wiley Online Library
More than 50% of human tumors carry TP 53 gene mutations and in consequence more
than 45,000 somatic and germline mutations have been gathered in the UMD TP 53 …
than 45,000 somatic and germline mutations have been gathered in the UMD TP 53 …
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung …
N Thatcher, FR Hirsch, AV Luft, A Szczesna… - The lancet …, 2015 - thelancet.com
Background Necitumumab is a second-generation, recombinant, human immunoglobulin
G1 EGFR antibody. In this study, we aimed to compare treatment with necitumumab plus …
G1 EGFR antibody. In this study, we aimed to compare treatment with necitumumab plus …
Applications and strategies in nanodiagnosis and nanotherapy in lung cancer
Lung cancer is the second most common cancer and the leading cause of death in both men
and women in the world. Lung cancer is heterogeneous in nature and diagnosis is often at …
and women in the world. Lung cancer is heterogeneous in nature and diagnosis is often at …
New insights into designing hybrid nanoparticles for lung cancer: Diagnosis and treatment
Lung cancer is the foremost reason of death from cancers with broad genetic and epigenetic
diversity. Various strategies are clinically available for diagnosis and treatment of lung …
diversity. Various strategies are clinically available for diagnosis and treatment of lung …